CN117297990A - Anti-aging composition and preparation method and application thereof - Google Patents
Anti-aging composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN117297990A CN117297990A CN202311593887.5A CN202311593887A CN117297990A CN 117297990 A CN117297990 A CN 117297990A CN 202311593887 A CN202311593887 A CN 202311593887A CN 117297990 A CN117297990 A CN 117297990A
- Authority
- CN
- China
- Prior art keywords
- parts
- proline
- glycerol
- rhamnose
- betaine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 82
- 239000004310 lactic acid Substances 0.000 claims abstract description 52
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 239000011521 glass Substances 0.000 claims abstract description 22
- 239000008367 deionised water Substances 0.000 claims abstract description 21
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 21
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 108010031318 Vitronectin Proteins 0.000 claims abstract description 16
- 102100035140 Vitronectin Human genes 0.000 claims abstract description 16
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 29
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 15
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- 229960003237 betaine Drugs 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 11
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 11
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 23
- 238000010521 absorption reaction Methods 0.000 abstract description 12
- 230000003020 moisturizing effect Effects 0.000 abstract description 10
- 239000013543 active substance Substances 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 15
- 210000004127 vitreous body Anatomy 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 210000002510 keratinocyte Anatomy 0.000 description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 11
- 229920002674 hyaluronan Polymers 0.000 description 11
- 229960003160 hyaluronic acid Drugs 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- KOGFZZYPPGQZFZ-QVAPDBTGSA-N (2s,3r,4s,5r)-2-(2-hydroxypropyl)oxane-3,4,5-triol Chemical compound CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O KOGFZZYPPGQZFZ-QVAPDBTGSA-N 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000530268 Lycaena heteronea Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of cosmetics, in particular to an anti-aging composition, a preparation method and application thereof. The anti-aging composition comprises the following components: vitronectin, deionized water, pentanediol, and a supramolecular solvent comprising proline-rhamnose-glycerol and betaine-lactic acid. According to the invention, two supermolecular solvents, namely proline-rhamnose-glycerol and betaine-lactic acid, are used for delivering the vitronectin, so that the absorption of the vitronectin is effectively promoted, and the problems of skin feel and absorption of the vitronectin are solved. The supermolecular solvents proline-rhamnose-glycerol and betaine-lactic acid are also components in the active substances with the efficacy of cosmetics, and can protect the structure of the active substances and play a role in synergy while promoting the absorption of the active substances, so that the effects of resisting ageing, repairing and moisturizing of the vitrein are improved. When the same amount of glass color is used, the composition has better anti-aging, repairing and moisturizing effects compared with the existing composition without the supermolecule solvent.
Description
Technical Field
The invention relates to the field of cosmetics, in particular to an anti-aging composition, a preparation method and application thereof.
Background
The hydroxypropyl tetrahydropyran triol, also called as vitriol, has wide biological potential, can promote the generation of hyaluronic acid, promote the synthesis of collagen, help the tight combination of epidermis and dermis, promote the synthesis of mucopolysaccharide and help the dermis to maintain elasticity, so that the vitriol is regarded as an anti-aging 'immortal component' by some consumers. From some documents of the vitreogenesis, the biological activity of the vitreogenesis is weak, and a certain concentration is needed to be achieved to work. The glass color factor in the formula has the mass concentration of 3% -10%, and the concentration is higher than 3%, so that the effect can be achieved, but the higher the concentration is, the more effective is. In fact, the effect of the vitriol depends not only on the concentration added, but also on the absorption of it by the skin. When the concentration is high, the viscosity may be increased first, resulting in deterioration of skin feel; and secondly, the vitriol contains four hydroxyl groups, the vitriol can be enriched on the surface of the skin and in the stratum corneum, only a small amount of vitriol can enter the dermis layer and is easily decomposed by related protease in the skin, so that the bioavailability of the vitriol is low, the cost is increased and the like.
The Mijia supermolecule glass color factor cream of the 'national good black horse' has higher content of glass color factor components, and the product also surrounds the glass color factor application for patent CN115737515A, and the glass color factor is compounded with active components such as dipeptide diamino Ding Xianbian-base amide diacetate and the like. Patent CN112402310a is directed to the formulation of anti-wrinkle eye cream from vitronectin and polypeptides such as hexapeptide-9, palmitoyl pentapeptide-4, etc. In the patent CN111588657A, the vitriol and the blue copper peptide are compounded into essence, so that the skin aging problem is solved. The products all use the vitreous factor to match with other components to realize the anti-aging effect, but the problems of skin feel and absorption of the vitreous factor are not solved, so that the discovery of a method capable of improving the bioavailability of the vitreous factor is important.
Accordingly, the prior art is still in need of improvement and development.
Disclosure of Invention
In view of the shortcomings of the prior art, the invention aims to provide an anti-aging composition, a preparation method and application thereof, and aims to solve the problems of poor skin feel and low bioavailability of the vitreous pigment when the concentration of the vitreous pigment in the existing composition is high.
The technical scheme of the invention is as follows:
in a first aspect of the invention, there is provided a composition comprising the following components: the preparation method comprises the steps of vitriol, deionized water, pentanediol and a supermolecule solvent, wherein the supermolecule solvent comprises proline-rhamnose-glycerol and betaine-lactic acid, the proline-rhamnose-glycerol is obtained by mixing proline, rhamnose and glycerol, heating and stirring, and the betaine-lactic acid is obtained by mixing betaine and lactic acid, heating and stirring.
Optionally, the composition comprises the following components in parts by weight: 10-30 parts of vitronectin, 40-60 parts of deionized water, 5-10 parts of pentanediol, 1-20 parts of proline-rhamnose-glycerol and 1-20 parts of betaine-lactic acid.
Optionally, the composition consists of the following components in parts by weight: 30 parts of vitronectin, 52 parts of deionized water, 6 parts of pentanediol, 10 parts of proline-rhamnose-glycerol and 2 parts of betaine-lactic acid.
The invention mainly utilizes two supermolecular solvents of proline-rhamnose-glycerol and betaine-lactic acid to deliver the vitronectin, thereby effectively promoting the absorption of the vitronectin and solving the problems of skin feel and absorption of the vitronectin. The supermolecular solvents proline-rhamnose-glycerol and betaine-lactic acid are also components in the active substances with the efficacy of cosmetics, and can protect the structure of the active substances and play a role in synergy while promoting the absorption of the active substances, so that the effects of resisting ageing, repairing and moisturizing of the vitrein are improved. When the same amount of glass color is used, the composition has better anti-aging, repairing and moisturizing effects compared with the existing composition without the supermolecule solvent.
Proline-rhamnose-glycerol: proline, which is commonly referred to as the "basic component of proteins". It is a main amino acid involved in collagen synthesis, and if proline is absent in collagen, it cannot be hydroxylated, and thus the stability of the structure of the triple helix of collagen is affected, thereby affecting the synthesis of the whole collagen. The rhamnose not only has very good moisturizing effect, can strengthen the natural protective barrier function of skin and reduce inflammatory reaction of skin, but also can promote the activity of skin fibroblasts, thereby promoting the synthesis of collagen and improving the smoothness and compactness of skin; the glycerol has the moisturizing effect, and forms the three into a supermolecule solvent, so that the respective effects are maintained, and the glass color factor can be delivered, thereby achieving the synergistic effect.
Betaine-lactic acid: the betaine has the function of moisture preservation, and the lactic acid is an extremely effective exfoliating component, can loosen horny layers, forms supermolecule solvents for the two components, not only maintains the respective effects, but also can deliver the vitriol factor, and has the synergistic effect.
Experiments have found that when other supramolecular solvents are used, such as: the delivery effects of proline-xylitol-glycerol, betaine-propylene glycol-glycerol, betaine-lactic acid and proline-rhamnose-glycerol are poor, and the combination of the two supermolecular solvents proline-rhamnose-glycerol and betaine-lactic acid delivers the vitrein. The addition of the two supermolecule solvents reduces the cost and increases the efficiency, obviously improves the absorption effect of the glassy factor, greatly improves the bioavailability of the glassy factor, and simultaneously indicates that not all supermolecule solvents have permeation promotion effect on the glassy factor and have high selectivity.
In a second aspect of the present invention, there is provided a method of preparing an anti-ageing composition comprising the steps of:
mixing the glass color factor, deionized water and pentanediol to obtain a glass color factor solution;
mixing the vitreous color factor solution with a supermolecule solvent, and stirring to obtain an anti-aging composition;
the supermolecular solvent comprises proline-rhamnose-glycerol and betaine-lactic acid, wherein the proline-rhamnose-glycerol is obtained by mixing proline, rhamnose and glycerol, heating and stirring, and the betaine-lactic acid is obtained by mixing betaine and lactic acid, heating and stirring.
Optionally, the method for preparing the anti-aging composition comprises the steps of:
mixing 10-30 parts of vitriol, 40-60 parts of deionized water and 5-10 parts of pentanediol to obtain a vitriol solution;
mixing the vitriol solution with 1-20 parts of proline-rhamnose-glycerol and 1-20 parts of betaine-lactic acid, and stirring to obtain the antiaging composition.
Optionally, the method for preparing the anti-aging composition comprises the steps of:
uniformly mixing 30 parts of glass color factor, 52 parts of deionized water and 6 parts of pentanediol to obtain a glass color factor solution;
and mixing the vitriol solution with 10 parts of proline-rhamnose-glycerol and 2 parts of betaine-lactic acid, and uniformly stirring to obtain the anti-aging composition.
Optionally, the preparation method of the proline-rhamnose-glycerol comprises the following steps:
mixing proline and glycerol, stirring for a first preset time at a first preset temperature, then cooling to 50-60 ℃, adding rhamnose, stirring for a second preset time at a second preset temperature, and then performing ultrasonic treatment for 10-30 minutes to obtain the proline-rhamnose-glycerol.
The proline-rhamnose-glycerol is obtained by mixing the hydrogen bond acceptor and the hydrogen bond donor, and stirring for a certain time under a heating condition.
Optionally, the molar ratio of proline, rhamnose and glycerol is 1:1:1-5:10:10.
optionally, the first preset temperature is 60-85 ℃, such as 60 ℃, 65 ℃, 70 ℃, 75 ℃, 85 ℃, and the first preset time is 1-5 hours, such as 1 hour, 2 hours, 3 hours, 4 hours, 5 hours.
Optionally, the second preset temperature is 50-60 ℃, such as 50 ℃, 55 ℃, 60 ℃, and the second preset time is 30-50 minutes, such as 30 minutes, 40 minutes, 50 minutes.
Optionally, the preparation method of betaine-lactic acid comprises the following steps:
mixing betaine and lactic acid, and stirring at a third preset temperature for a third preset time to obtain the betaine-lactic acid.
Wherein, betaine is used as hydrogen bond acceptor, lactic acid is used as hydrogen bond donor, the hydrogen bond acceptor and the hydrogen bond donor are mixed, and the mixture is stirred for a certain time under the heating condition, thus obtaining the betaine-lactic acid.
Optionally, the molar ratio of betaine to lactic acid is 1:1-5:10.
optionally, the third preset temperature is 50-80deg.C, such as 50deg.C, 55deg.C, 65deg.C, 70deg.C, 75deg.C, 80deg.C, and the third preset time is 1-3 hours, such as 1 hour, 2 hours, 3 hours.
In a third aspect of the invention there is provided the use of an anti-ageing composition according to the invention in cosmetics.
Drawings
FIG. 1 is a diagram of proline-rhamnose-glycerol 1 HNMR (hydrogen nuclear magnetic resonance spectroscopy) spectrogram, wherein the deuteration reagent is D 2 O。
FIG. 2 is a two-dimensional nuclear magnetic hydrogen NOESY (nuclear Europa Haoser effect spectrum) spectrum of proline-rhamnose-glycerol, in which the deuterating agent is D 2 O。
FIG. 3 is a proline-lactic acid 1 HNMR diagram in which deuterated reagent is D 2 O。
FIG. 4 is a two-dimensional nuclear magnetic resonance NOESY spectrum of proline-lactic acid in which the deuterating agent is D 2 O。
Figure 5 is an infrared spectrum of proline-rhamnose-glycerol, proline-lactic acid.
FIG. 6 is a graph showing the results of accumulated permeation of glass color per unit area at different time points.
FIG. 7 is a graph showing the result of 24h glass color retention per unit area.
FIG. 8 is a graph showing the trend of relative survival of human keratinocytes.
FIG. 9 is a graph showing the trend of relative survival of human dermal fibroblasts.
FIG. 10 is a graph showing comparison of human type I collagen content in different groups.
FIG. 11 is a graph showing the relative amounts of MMP-1 (matrix metalloproteinase-1) in different groups.
FIG. 12 is a graph showing comparison of the content of APQ3 protein (aquaporin 3) in different groups.
FIG. 13 is a graph showing comparison of immunofluorescence results of APQ3 protein expression in different groups.
Fig. 14 is a graph comparing HA (hyaluronic acid) content of different groups.
FIG. 15 is a graph showing the relative content of cell proliferation after injury to HaCaT cells (human immortalized keratinocytes) by different groups of SDS (sodium dodecyl sulfate).
Fig. 16 is a bar graph comparison of different sets of relative mobilities.
FIG. 17 is a comparison of cell migration pictures of different groups.
Detailed Description
The invention provides an anti-aging composition, a preparation method and application thereof, and aims to make the purposes, technical schemes and effects of the invention clearer and more definite, and the invention is further described in detail below. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
It is to be noted that the proline-rhamnose-glycerol referred to in the following examples and comparative examples was prepared by the following method:
mixing 1 mol of proline with 9 mol of glycerol, stirring for 3 hours at 70 ℃, then cooling to 55 ℃, adding 1 mol of rhamnose, stirring for 40 minutes at 55 ℃, and then carrying out ultrasonic treatment for 20 minutes to obtain the proline-rhamnose-glycerol. The proline-rhamnose-glycerol 1 The HNMR spectrogram, the two-dimensional nuclear magnetic resonance hydrogen NOESY spectrogram and the infrared spectrogram are respectively shown in figures 1, 2 and 5. From the slave 1 As can be seen in HNMR spectra, 1.0-2.0 ppm is-CH 2 3.0 to 4.0 ppm is-CH-or-CH 2 4.01 ppm is a characteristic peak of-OH. In addition, it can be seen from the two-dimensional nuclear magnetic hydrogen NOESY spectrum that the outside of the diagonal represents the interaction force between proline and glycerol and rhamnose, and the on the diagonal represents the intramolecular force, so that the successful preparation of proline-rhamnose-glycerol can be demonstrated.
The betaine-lactic acid referred to in the following examples and comparative examples was prepared by the following method:
1 mol of betaine and 1.709 mol of lactic acid were mixed and stirred at 65℃for 2 hours to obtain the betaine-lactic acid. The betaine-lactic acid 1 The HNMR spectrogram, the two-dimensional nuclear magnetic resonance hydrogen NOESY spectrogram and the infrared spectrogram are respectively shown in the figures 3, 4 and 5. From the slave 1 As can be seen in the HNMR spectra, 1.0-1.5 ppm is-CH 2 3.0 to 4.0 ppm is-CH 3 4.92 ppm is a characteristic peak of-OH. In addition, as can be seen from the two-dimensional nuclear magnetic resonance hydrogen NOESY spectrum, the outside of the diagonal (black circle) represents the interaction force between betaine and lactic acid, and the on the diagonal represents the intramolecular force, so that the successful preparation of betaine-lactic acid supermolecule can be demonstrated.
Example 1:
according to parts by weight, 30 parts of the vitreous humor powder, 54 parts of deionized water and 6 parts of pentanediol are uniformly mixed at room temperature to obtain the vitreous humor solution 1. And mixing the vitriol solution 1 with 10 parts of glycerol, and stirring uniformly to obtain the anti-aging composition.
Example 2:
according to parts by weight, 30 parts of the vitreous humor powder, 49 parts of deionized water and 6 parts of pentanediol are uniformly mixed at room temperature to obtain the vitreous humor solution 2. And mixing the vitriol solution 2 with 5 parts of betaine-lactic acid and 10 parts of glycerol, and uniformly stirring to obtain the anti-aging composition.
Example 3:
at room temperature, 30 parts of the vitreous humor powder, 44 parts of deionized water and 6 parts of pentanediol are uniformly mixed to obtain a vitreous humor solution 3. And mixing the vitriol solution 3 with 20 parts of proline-rhamnose-glycerol, and uniformly stirring to obtain the anti-aging composition.
Example 4:
according to parts by weight, 30 parts of the vitreous humor powder, 52 parts of deionized water and 6 parts of pentanediol are uniformly mixed at room temperature to obtain a vitreous humor solution 4. And mixing the vitriol solution 4 with 10 parts of proline-rhamnose-glycerol and 2 parts of betaine-lactic acid, and uniformly stirring to obtain the anti-aging composition.
Comparative example 1:
according to parts by weight, 30 parts of the vitreous humor powder, 44 parts of deionized water and 6 parts of pentanediol are uniformly mixed at room temperature to obtain a vitreous humor solution 5. And mixing the vitriol solution 5 with 20 parts of betaine-propylene glycol-glycerin, and uniformly stirring to obtain the anti-aging composition.
Comparative example 2:
according to parts by weight, 30 parts of the vitreous humor powder, 44 parts of deionized water and 6 parts of pentanediol are uniformly mixed at room temperature to obtain a vitreous humor solution 6. And mixing the vitriol solution 6 with 20 parts of proline-xylitol-glycerol, and uniformly stirring to obtain the anti-aging composition.
Comparative example 3:
according to parts by weight, 30 parts of the vitreous humor powder, 49 parts of deionized water and 6 parts of pentanediol are uniformly mixed at room temperature to obtain a vitreous humor solution 7. The vitriol solution 7 is mixed with 10 parts of proline-xylitol-glycerol and 5 parts of HEPES (4-hydroxyethyl piperazine ethane sulfonic acid) and stirred uniformly to obtain the anti-aging composition.
To verify the bioavailability of the vitronectin, the following characterization was performed:
the anti-aging compositions obtained in each example were tested for transmittance in an in vitro transdermal condition. The in vitro transdermal experiments used Franz diffusion Chi Fa, were performed as follows: and carrying out a transdermal diffusion test by adopting a TP-6 intelligent transdermal diffusion instrument, wherein the tester is provided with 6 diffusion cells at the same time, the cell opening area is 2.5cm, and the volume of each cell is 7.5mL. The transdermal rate was calculated as the average of 6 pool samples using 0.9% physiological saline as the receiving fluid. The skin of the pig is taken as the permeable skin, the subcutaneous fat of the pig skin is removed, and after the foreign hair is removed, the pig skin is washed by sterile normal saline and is detected by a diffusion cell.
The experimental results are as follows:
as can be seen from fig. 6 and 7:
overall transdermal effect: example 4> comparative example 1> comparative example 2> comparative example 3> example 3.
The anti-aging composition of example 4 (hereinafter also abbreviated as a sample) was selected for efficacy verification and compared with a vitreous factor solution (30 parts of vitreous factor powder+6 parts of pentanediol+64 parts of deionized water as a blank), and the following was specifically tested:
test example 1
Safety test of the anti-aging composition prepared in example 4
1. Human keratinocyte cytotoxicity detection and human dermal fibroblast cytotoxicity detection
Samples were subjected to cytotoxicity assay on human keratinocytes: after the samples were diluted to various volume concentrations with the minimum essential medium (MEM medium), the samples were tested using a thiazole blue (MTT) model, and the test results are shown in fig. 8;
samples were subjected to cytotoxicity assay on human dermal fibroblasts: samples were diluted with low sugar DMEM medium to various volume concentrations and tested in MTT model, and the test results are shown in fig. 9.
Conclusion:
as can be seen from fig. 8 to 9:
based on human keratinocytes, the sample has IC 50=10.59% (95% ci: 9.481-12.03%), IC 90=0.892%;
based on human dermal fibroblasts, the sample had an IC 50= 7.095% (95% ci: 5.369-10.43%) and an IC 90=0.184%.
Test example 2
Anti-wrinkle efficacy evaluation of the anti-aging composition of example 4 based on human dermal fibroblasts
1. Type I collagen assay
The anti-aging composition was subjected to type I collagen content assay on human dermal fibroblasts, and the assay was performed by enzyme-linked immunosorbent assay (ELISA), the assay results of which are shown in FIG. 10.
Conclusion of experiment:
compared with NC group, the content of human type I collagen in PC group is obviously increased (P < 0.05), which indicates that the positive control of the test is effective;
compared with NC group, the anti-aging composition has the advantages that the content of human type I collagen is obviously increased (P < 0.05) at the test concentration of 0.25%, 0.125% and 0.06%, the up-regulation rates are 29.94%, 51.89% and 22.45%, respectively, the anti-aging composition has the capability of promoting the synthesis of human type 1 collagen at the concentration of 0.25%, 0.125% and 0.06%, the effect of promoting the synthesis of human type 1 collagen is better than that of vitronectin (blank group), and the anti-wrinkle and tightening effects are better achieved.
2. MMP-1 release test
And (3) stimulating the fibroblasts by using UVA, carrying out RNAiso Plus treatment on the fibroblasts, and carrying out RNA extraction, reverse transcription and fluorescent quantitative PCR operation according to the operation instruction of the HA ELISA kit.
MMP is matrix metalloproteinase, and has the main effects of degrading collagen, and reducing collagen degradation degree after MMP content is reduced, thereby achieving certain anti-wrinkle effect.
The results are shown in fig. 11, and as can be seen from fig. 11:
compared with the BC group, the relative MMP-1 content of the NC group is obviously increased, which proves that the test stimulation is effective;
compared with the NC group, the relative MMP-1 content of the PC group is obviously reduced, which proves that the positive control of the test is effective;
compared with NC group, the relative content of MMP-1 is obviously reduced (P < 0.05) at 0.25%, 0.125% and 0.06%, the inhibition rate is 52.20%, 27.72% and 19.32%, respectively, the anti-aging composition has the effect of inhibiting the release of MMP-1 at 0.25%, 0.125% and 0.06%, and the anti-aging effect of the anti-aging composition is better than that of 0.25% vitrine (blank) at 0.25% and 0.125%, so that the anti-aging effect can be better achieved.
Test example 3
1. Determination of APQ3 protein content in human keratinocytes
The samples were set at 2 volume concentrations and APQ3 protein expression assays were performed on human keratinocytes to evaluate the efficacy of the anti-aging composition of example 4.
The results are shown in FIGS. 12 to 13, and as can be seen from FIGS. 12 to 13:
compared with the BC group, the relative content of APQ3 in the PC group is obviously increased (P < 0.05), which proves that the positive control of the test is effective;
compared with the BC group, the relative content of APQ3 is obviously increased (P is less than 0.05) at the test concentration of 0.4 percent and 0.2 percent (volume concentration), and the up-regulation rates are 58.07 percent and 29.92 percent respectively, so that the anti-aging composition has the effect of promoting the expression of APQ3 protein at the concentrations of 0.4 percent and 0.2 percent, thereby achieving the moisturizing effect and having better effect than that of the vitronectin (blank) group.
Human keratinocyte hyaluronic acid HA synthesis content determination
The sample volume concentration is set to be 0.8%, HA synthesis content measurement experiments are carried out on human keratinocytes, and detection is carried out by an ELISA method.
As a result, as shown in fig. 14, it can be seen from fig. 14:
compared with NC group, HA synthesis content of PC group is obviously increased (P < 0.05), which indicates that the positive control of the test is effective;
compared with NC group, the anti-aging composition HAs remarkably increased HA synthesis content (P < 0.05) at 0.8% volume concentration, and up-regulation rate of 3.36%;0.8% glass color factor (blank), the HA synthesis content is obviously reduced; it indicates that the ability of the anti-aging composition to promote hyaluronic acid synthesis at a concentration of 0.8% is better than 0.8% of the glass color factor (blank). Therefore, the moisturizing effect can be achieved.
Test example 4
1. Proliferation detection experiment after SDS injury to HaCaT cells
Cell damage treatment was performed by setting the SDS concentration to 60. Mu.g/mL, and the sample volume concentrations were set to 0.4%, 0.2% and 0.1%, respectively, and the proliferation experiment after SDS damage to HaCaT cells was performed on human keratinocytes.
As a result, as shown in fig. 15, it can be seen from fig. 15:
compared with the BC group, the cell number of the NC group is obviously reduced (P < 0.05), which indicates that the stimulation condition of the test is effective;
compared with the NC group, the cell number of the PC group is obviously increased (P < 0.05), which proves that the positive control of the test is effective;
compared with NC group, the anti-aging composition has significantly increased cell number (P < 0.05) at 0.4%, 0.2%, 0.1% test concentration (volume concentration), and repair rates of 41.20%, 35.40%, 33.41%, respectively; the cell number is obviously increased (P < 0.05) under the test concentration of 0.4% by the glass color factor (blank), and the repair rate is 35.18%; it is indicated that the anti-aging composition has a proliferation effect on SDS-injured HaCaT cells at a concentration of 0.4%, 0.2%, 0.1%, and the proliferation effect of the anti-aging composition is superior to that of vitronectin (blank) at a concentration of 0.4%, so that the repairing effect of the anti-aging composition is better.
2. Human keratinocyte scratch test
The results of the cell scarification test of the sample on human keratinocytes are shown in FIGS. 16 to 17, and can be seen from FIGS. 16 to 17:
the relative mobility of the PC group increased (P < 0.05) at 24h compared to NC group, indicating that the positive control of this test was valid;
the relative mobility of the anti-aging composition was significantly increased (P < 0.05) at the test concentration of 0.2% and 0.1% (by volume) compared to NC group, the repair rate was 207% and 144% respectively, the vitreous factor (blank) was significantly increased at the test concentration of 0.2%, and the repair rate was 36%, indicating that the repair efficacy of the anti-aging composition at the concentration of 0.2% was superior to that of the vitreous factor (blank) at the same concentration.
In summary, the anti-aging composition and the preparation method and application thereof provided by the invention mainly utilize two supermolecular solvents, namely proline-rhamnose-glycerol and betaine-lactic acid, to deliver the vitriol, so that the absorption of the vitriol is effectively promoted, and the problems of skin feel and absorption of the vitriol are solved. The supermolecular solvents proline-rhamnose-glycerol and betaine-lactic acid are also components in the active substances with the efficacy of cosmetics, and can protect the structure of the active substances and play a role in synergy while promoting the absorption of the active substances, so that the effects of resisting ageing, repairing and moisturizing of the vitrein are improved. When the same amount of glass color is used, the composition has better anti-aging, repairing and moisturizing effects compared with the existing composition without the supermolecule solvent.
It is to be understood that the invention is not limited in its application to the examples described above, but is capable of modification and variation in light of the above teachings by those skilled in the art, and that all such modifications and variations are intended to be included within the scope of the appended claims.
Claims (10)
1. An anti-aging composition comprising the following components: the preparation method comprises the steps of vitriol, deionized water, pentanediol and a supermolecule solvent, wherein the supermolecule solvent comprises proline-rhamnose-glycerol and betaine-lactic acid, the proline-rhamnose-glycerol is obtained by mixing proline, rhamnose and glycerol, heating and stirring, and the betaine-lactic acid is obtained by mixing betaine and lactic acid, heating and stirring.
2. The anti-aging composition according to claim 1, comprising the following components in parts by weight: 10-30 parts of vitronectin, 40-60 parts of deionized water, 5-10 parts of pentanediol, 1-20 parts of proline-rhamnose-glycerol and 1-20 parts of betaine-lactic acid.
3. The anti-aging composition according to claim 2, characterized in that it consists of the following components in parts by weight: 30 parts of vitronectin, 52 parts of deionized water, 6 parts of pentanediol, 10 parts of proline-rhamnose-glycerol and 2 parts of betaine-lactic acid.
4. A method of preparing an anti-aging composition comprising the steps of:
mixing the glass color factor, deionized water and pentanediol to obtain a glass color factor solution;
mixing the vitreous color factor solution with a supermolecule solvent, and stirring to obtain an anti-aging composition;
the supermolecular solvent comprises proline-rhamnose-glycerol and betaine-lactic acid, wherein the proline-rhamnose-glycerol is obtained by mixing proline, rhamnose and glycerol, heating and stirring, and the betaine-lactic acid is obtained by mixing betaine and lactic acid, heating and stirring.
5. The method of preparing an anti-aging composition according to claim 4, comprising the steps of:
mixing 10-30 parts of vitriol, 40-60 parts of deionized water and 5-10 parts of pentanediol to obtain a vitriol solution;
mixing the vitriol solution with 1-20 parts of proline-rhamnose-glycerol and 1-20 parts of betaine-lactic acid, and stirring to obtain the antiaging composition.
6. The method of preparing an anti-aging composition according to claim 5, comprising the steps of:
uniformly mixing 30 parts of glass color factor, 52 parts of deionized water and 6 parts of pentanediol to obtain a glass color factor solution;
and mixing the vitriol solution with 10 parts of proline-rhamnose-glycerol and 2 parts of betaine-lactic acid, and uniformly stirring to obtain the anti-aging composition.
7. The method of preparing an anti-aging composition according to claim 4, wherein the method of preparing proline-rhamnose-glycerol comprises the steps of:
mixing proline and glycerol, stirring for a first preset time at a first preset temperature, then cooling to 50-60 ℃, adding rhamnose, stirring for a second preset time at a second preset temperature, and then performing ultrasonic treatment for 10-30 minutes to obtain the proline-rhamnose-glycerol.
8. The method of preparing an anti-aging composition according to claim 7, wherein the molar ratio of proline, rhamnose and glycerol is 1:1:1-5:10:10;
the first preset temperature is 60-85 ℃, and the first preset time is 1-5 hours;
the second preset temperature is 50-60 ℃, and the second preset time is 30-50 minutes.
9. The method of preparing an anti-aging composition according to claim 4, wherein the method of preparing betaine-lactic acid comprises the steps of:
mixing betaine and lactic acid, and stirring at a third preset temperature for a third preset time to obtain the betaine-lactic acid;
the molar ratio of betaine to lactic acid is 1:1-5:10;
the third preset temperature is 50-80 ℃, and the third preset time is 1-3 hours.
10. Use of an anti-ageing composition as claimed in any of claims 1 to 3 in cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311593887.5A CN117297990B (en) | 2023-11-27 | 2023-11-27 | Anti-aging composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311593887.5A CN117297990B (en) | 2023-11-27 | 2023-11-27 | Anti-aging composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117297990A true CN117297990A (en) | 2023-12-29 |
| CN117297990B CN117297990B (en) | 2024-03-19 |
Family
ID=89288692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311593887.5A Active CN117297990B (en) | 2023-11-27 | 2023-11-27 | Anti-aging composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117297990B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118319777A (en) * | 2024-04-16 | 2024-07-12 | 宁波伯通伟达生物医药有限公司 | Supermolecule vitreous color factor composition with skin multi-target anti-aging effect and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011354A1 (en) * | 2020-12-09 | 2022-06-15 | Beiersdorf AG | New cosmetics solvents based on two different components |
| US20230139504A1 (en) * | 2021-10-31 | 2023-05-04 | L'oreal | Cosmetic compositions comprising high amounts of hydroxypropyl tetrahydropyrantriol |
| CN116509748A (en) * | 2023-05-26 | 2023-08-01 | 深圳杉海创新技术有限公司 | Anti-wrinkle composition and preparation method and application thereof |
| CN116617108A (en) * | 2023-06-01 | 2023-08-22 | 深圳杉海创新技术有限公司 | Anti-wrinkle composition and anti-wrinkle cosmetic |
| CN117018672A (en) * | 2023-08-29 | 2023-11-10 | 北京理工大学重庆创新中心 | Ternary eutectic solvent containing vitriol factor and preparation method and application thereof |
-
2023
- 2023-11-27 CN CN202311593887.5A patent/CN117297990B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011354A1 (en) * | 2020-12-09 | 2022-06-15 | Beiersdorf AG | New cosmetics solvents based on two different components |
| US20230139504A1 (en) * | 2021-10-31 | 2023-05-04 | L'oreal | Cosmetic compositions comprising high amounts of hydroxypropyl tetrahydropyrantriol |
| CN116509748A (en) * | 2023-05-26 | 2023-08-01 | 深圳杉海创新技术有限公司 | Anti-wrinkle composition and preparation method and application thereof |
| CN116617108A (en) * | 2023-06-01 | 2023-08-22 | 深圳杉海创新技术有限公司 | Anti-wrinkle composition and anti-wrinkle cosmetic |
| CN117018672A (en) * | 2023-08-29 | 2023-11-10 | 北京理工大学重庆创新中心 | Ternary eutectic solvent containing vitriol factor and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| "SHINE+双擎玻色因，增效不堆量，应用超分子溶剂解决透皮促渗难题", Retrieved from the Internet <URL:https://mp.weixin.qq.com/s/Nh0AM6JpJ6v4b0W5FwvxJw> * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118319777A (en) * | 2024-04-16 | 2024-07-12 | 宁波伯通伟达生物医药有限公司 | Supermolecule vitreous color factor composition with skin multi-target anti-aging effect and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117297990B (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7227903B2 (en) | Compounds useful for the treatment and/or care of skin, hair, nails and/or mucous membranes | |
| CN117297990B (en) | Anti-aging composition and preparation method and application thereof | |
| EP3648784B1 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| JP5938787B2 (en) | Novel sirtuin 6 activating peptide and cosmetic or pharmaceutical composition containing the same | |
| US8877713B2 (en) | Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same | |
| US8435950B2 (en) | Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same | |
| JP2003238387A (en) | Skin care preparation composition for mitigating pouch and dark area under eye | |
| CN112156033B (en) | Essence containing ultra-small molecule sodium hyaluronate and preparation method thereof | |
| KR102263479B1 (en) | Cosmetic composition for anti-aging comprising heat-killed Lactobacillus plantarum or culture of the Lactobacillus plantarum | |
| KR20140043727A (en) | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | |
| JP2008534658A (en) | Cosmetic or dermatological pharmaceutical composition comprising an enkephalin-derived peptide for reducing and / or removing facial wrinkles | |
| CN116509748A (en) | Anti-wrinkle composition and preparation method and application thereof | |
| CN112545955A (en) | Anti-aging repair composition and preparation method and application thereof | |
| CN111631985A (en) | Anti-wrinkle composition containing folic acid, eye cream and preparation method thereof | |
| KR101261065B1 (en) | Synthetic peptides reducing or removing bags formed under lower eye contour and their use in cosmetic or dermopharmaceutical compositions | |
| CN111632002A (en) | Whitening anti-inflammatory composition and application and preparation method thereof | |
| CN115400043A (en) | Anti-wrinkle composition, preparation method thereof and application thereof in cosmetics | |
| CN111588650A (en) | Repairing composition, repairing mask liquid and repairing mask | |
| CN115403462B (en) | Supermolecule succinic acid solvent, supermolecule modified elastin, and preparation methods and applications thereof | |
| CN114085266B (en) | Peptide conjugate derivative based on palmitoyl tetrapeptide-7, preparation method and application | |
| CN115350113A (en) | Composition containing peptide and application thereof | |
| KR102281606B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex | |
| JPH0543424A (en) | External agent for use in hair | |
| CN114805601A (en) | Application of polypeptide analogue in anti-wrinkle and anti-aging | |
| CN109010113B (en) | Composition for repairing sensitive skin and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |